NYT: Amgen close to buying Onyx for
$125/share
- The paper adds a deal could be "announced as soon as Monday," while cautioning "talks are ongoing and could still fall apart."
- The reported price would represent a 7% premium to Onyx's (ONXX) Friday close of $116.96.
- Amgen (AMGN) reportedly revised its bid from a prior $130/share after failing to obtain trial data related to Onyx's Kyprolis blood-cancer drug. The company is still paying a steep 10.5x 2014E sales.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com